Over the past year, there have been promising results from multiple early stage clinical trials evaluating cancer vaccines, one type of immunotherapy, in pancreatic cancer patients. From the AMPLIFY-201 trial […]
Targeting immune suppression to treat pancreatic cancer
While immunotherapy has transformed the clinical landscape for various solid malignancies, most notably melanoma and lung cancer, pancreatic ductal adenocarcinoma (PDAC) remains exceptionally recalcitrant to these T-cell-activating modalities. This profound […]
Overcoming immunotherapy resistance in pancreatic cancer
Immunotherapy, a type of treatment aimed at engaging the immune system – namely, T cells – to attack and kill cancer cells, has had success and redefined care in multiple […]
Researchers Aim to Prevent Liver Metastasis in Pancreatic Cancer Patients
Pancreatic cancer is still one of the most lethal cancers, in part, because it has spread or metastasized by the time it is diagnosed. One common site of metastasis for […]
Engineering CAR T cells to overcome immune suppression in pancreatic cancer
Chimeric antigen receptor (CAR) T cells, an immunotherapy that has been successful in treating blood cancers, has had limited efficacy in solid tumors including in pancreatic cancer. Greg Allen, MD, […]
First RAS inhibitor approved by the FDA
Today daraxonrasib, an oral RAS(ON) multi-selective inhibitor from Revolution Medicines, was approved by the FDA for use by patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) or for patients […]